- Home
- RC vs ORKA Comparison
RC vs ORKA Comparison
Compare RC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- ORKA
- Stock Information
- Founded
- RC 2007
- ORKA 2004
- Country
- RC United States
- ORKA United States
- Employees
- RC N/A
- ORKA N/A
- Industry
- RC Real Estate Investment Trusts
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RC Real Estate
- ORKA Health Care
- Exchange
- RC Nasdaq
- ORKA Nasdaq
- Market Cap
- RC 755.3M
- ORKA 354.2M
- IPO Year
- RC N/A
- ORKA N/A
- Fundamental
- Price
- RC $4.43
- ORKA $14.21
- Analyst Decision
- RC Hold
- ORKA Strong Buy
- Analyst Count
- RC 7
- ORKA 8
- Target Price
- RC $7.54
- ORKA $39.71
- AVG Volume (30 Days)
- RC 2.0M
- ORKA 364.0K
- Earning Date
- RC 08-06-2025
- ORKA 08-15-2025
- Dividend Yield
- RC 10.89%
- ORKA N/A
- EPS Growth
- RC N/A
- ORKA N/A
- EPS
- RC N/A
- ORKA N/A
- Revenue
- RC N/A
- ORKA N/A
- Revenue This Year
- RC N/A
- ORKA N/A
- Revenue Next Year
- RC $33.07
- ORKA N/A
- P/E Ratio
- RC N/A
- ORKA N/A
- Revenue Growth
- RC N/A
- ORKA N/A
- 52 Week Low
- RC $3.93
- ORKA $5.49
- 52 Week High
- RC $9.54
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- RC 47.54
- ORKA N/A
- Support Level
- RC $4.39
- ORKA N/A
- Resistance Level
- RC $4.73
- ORKA N/A
- Average True Range (ATR)
- RC 0.16
- ORKA 0.00
- MACD
- RC -0.00
- ORKA 0.00
- Stochastic Oscillator
- RC 25.58
- ORKA 0.00
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.